Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thrombotic burden and longitudinal outcomes in Thai patients with polycythemia vera.

Annals of medicine·2026
Same author

Perioperative Outcomes in Factor XI Deficiency: A Systematic Review.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Developing a core outcome set for the NeuroPoint Alliance Quality Outcomes Database Pediatric Tumor Surgery Registry: a modified Delphi study.

Journal of neuro-oncology·2026
Same author

Binational patterns in use of Food is Medicine among Mexican immigrants.

Frontiers in nutrition·2026
Same author

Iron Overload-Associated Oxidative Stress and Immune Cell Dysfunction in Thalassemia: Integrative Analysis of Hematological, Biochemical, and Flow Cytometric Biomarkers.

Antioxidants (Basel, Switzerland)·2026
Same author

Outcomes of Intracranial Haemorrhage in Patients Taking Direct Oral Anticoagulants or Vitamin K Antagonists: A Seven-Year Single-Centre Retrospective Analysis.

Clinics and practice·2026

Related Experiment Video

Updated: Apr 14, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

2.2K

Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.

Bethany Samuelson1, Chatree Chai-Adisaksopha2, David Garcia3

  • 1Department of Hematology, University of Washington, 1100 Fairview Ave N, D5-100, PO Box 19024, Seattle, WA, 98109-1024, USA. bts99@uw.edu.

Journal of Thrombosis and Thrombolysis
|April 21, 2015
PubMed
Summary

Hydroxyurea is recommended over anagrelide for essential thrombocythemia (ET) treatment due to lower major bleeding rates. Both agents show similar efficacy in reducing thrombosis, with hydroxyurea offering a composite benefit in ET management.

Keywords:
AnagrelideEssential thrombocythemiaHydroxyureaMyeloproliferative neoplasms

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.6K

Related Experiment Videos

Last Updated: Apr 14, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

2.2K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.6K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Essential thrombocythemia (ET) management relies on cytoreductive therapy to mitigate thrombotic risk.
  • The optimal choice between anagrelide and hydroxyurea for ET treatment remains uncertain.
  • Low-dose aspirin is often used adjunctively in ET management.

Purpose of the Study:

  • To conduct a meta-analysis comparing anagrelide and hydroxyurea in ET patients.
  • To evaluate the comparative efficacy and safety of anagrelide versus hydroxyurea regarding thrombosis, bleeding, and mortality.
  • To determine the preferred first-line cytoreductive agent for essential thrombocythemia.

Main Methods:

  • Systematic literature search for randomized controlled trials comparing anagrelide and hydroxyurea in ET.
  • Inclusion of two relevant published studies in the meta-analysis.
  • Fixed-effects meta-analysis to compare rates of thrombosis, bleeding, and death.

Main Results:

  • Thrombosis rates were comparable between hydroxyurea and anagrelide (RR 0.86, 95% CI 0.64-1.16).
  • Major bleeding rates were significantly lower with hydroxyurea (RR 0.37, 95% CI 0.18-0.75).
  • No significant difference in acute myeloid leukemia progression (RR 1.50, 95% CI 0.43-5.29); composite outcome favored hydroxyurea (RR 0.78, 95% CI 0.63-0.97).

Conclusions:

  • Hydroxyurea is supported as a first-line cytoreductive agent for ET, primarily due to reduced major bleeding.
  • Anagrelide demonstrates comparable efficacy in preventing thrombotic events.
  • Anagrelide serves as a viable alternative for ET patients intolerant to hydroxyurea.